This review summarises important pharmacological and clinical characteristics of the orally administered, small-molecule, JAK inhibitor upadacitinib (Rinvoq®) in adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy. This review presents efficacy and tolerability outcomes when upadacitinib was evaluated in monotherapy studies (MEASURE UP 1 and 2) or in a study where it was used in combination with topical corticosteroids (AD UP).
Please login below to download this issue (PDF)